Wedbush Thinks Aquestive Therapeutics Inc’s Stock is Going to Recover
Wedbush analyst Liana Moussatos reiterated a Buy rating on Aquestive Therapeutics Inc (NASDAQ: AQST) today and set a price target of $34. The company’s shares opened today at $14.80, close to its 52-week low of $13.81.
According to TipRanks.com, Moussatos is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -2.3% and a 39.5% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Allena Pharmaceuticals Inc, Catabasis Pharmaceuticals, and Global Blood Therapeutics.
Aquestive Therapeutics Inc has an analyst consensus of Strong Buy, with a price target consensus of $27.75.
See today’s analyst top recommended stocks >>
The company has a one-year high of $20.70 and a one-year low of $13.81. Currently, Aquestive Therapeutics Inc has an average volume of 203.8K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aquestive Therapeutics, Inc. is a specialty pharmaceutical company focused on identifying, developing, and commercializing differentiated products to address unmet medical needs. The company has a late-stage proprietary product pipeline focused on the treatment of Central nervous system (CNS) diseases, as well as orally-administered complex molecules that can be alternatives to invasively-administered standard of care therapies. Its product candidates include Libervant, Sympazan, and AQST-117 (Riluzole). Aquestive Therapeutics develops and delivers drugs via its PharmFilm® technology. The company also collaborates with pharmaceutical partners to bring new molecules to market in differentiated and highly-marketable dosage forms. In addition to its proprietary product candidates, the company, with its partners, has a portfolio of development-stage products and commercialized products, such as Suboxone, a prescription medicine for the treatment of opioid dependence. The company was founded in January 2004 and is headquartered in Warren, NJ.